Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion
MLex Summary: Neurocrine Biosciences has agreed to acquire Soleno Therapeutics in an all-cash transaction at $53 per share, representing a total approximate value of $2.9 billion, the companies announced. The deal, which adds...To view the full article, register now.
Already a subscriber? Click here to view full article